Delavirdine adverse reactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==ADVERSE REACTIONS==


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher =  | date =  | accessdate =  }}</ref>
The safety of RESCRIPTOR Tablets alone and in combination with other therapies has been studied in approximately 6,000 patients receiving RESCRIPTOR. The majority of adverse events were of mild or moderate (i.e., ACTG Grade 1 or 2) intensity. The most frequently reported drug-related adverse event (i.e., events considered by the investigator to be related to the blinded study medication or events with an unknown or missing causal relationship to the blinded medication) among patients receiving RESCRIPTOR was skin rash.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=eb28dcd2-c457-4137-9eec-00062e5a601b | publisher =  | date =  | accessdate =  }}</ref>
 
{|
|[[File:Deladverse.JPG|800px|thumb]]
|}


==References==
==References==

Revision as of 23:19, 1 January 2014

Delavirdine
RESCRIPTOR® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

ADVERSE REACTIONS

The safety of RESCRIPTOR Tablets alone and in combination with other therapies has been studied in approximately 6,000 patients receiving RESCRIPTOR. The majority of adverse events were of mild or moderate (i.e., ACTG Grade 1 or 2) intensity. The most frequently reported drug-related adverse event (i.e., events considered by the investigator to be related to the blinded study medication or events with an unknown or missing causal relationship to the blinded medication) among patients receiving RESCRIPTOR was skin rash.[1]

References

  1. "RESCRIPTOR (DELAVIRDINE MESYLATE) TABLET [VIIV HEALTHCARE COMPANY]".

Adapted from the FDA Package Insert.